Abbott bets on cancer screening with $23 billion Exact Sciences deal

Go back to Abbott bets on cancer screening with $23 billion Exact Sciences deal

Guggenheim Downgrades Exact Sciences (EXAS) to Neutral

November 20, 2025 11:49 AM EST

Guggenheim analyst Subbu Nambi downgraded Exact Sciences (NASDAQ: EXAS) from Buy to Neutral.

For an analyst ratings summary and ratings history on Exact Sciences click here. For more ratings news on Exact Sciences click here.

Shares of Exact Sciences closed at $86.18 yesterday.

... More